AlphaNavi Pharma Exercises Option Regarding DSP-3905 under Development for Neuropathic Pain from Sumitomo Pharma
Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura; “Sumitomo Pharma”) and AlphaNavi Pharma Inc. (Head Office: Suita, Osaka, Japan; President and CEO: Yoshihiro Oyamada; “AlphaNavi”) announced today that, AlphaNavi exercised its option rights to obtain the worldwide exclusive license to develop, manufacture, and commercialize DSP-3905 (development code) currently under development for neuropathic pain by Sumitomo Pharma. Please see the attached press release in detail.